WO2023192779A3 - Combined prevention and treatment of patients with respiratory diseases caused by rna viral infections - Google Patents

Combined prevention and treatment of patients with respiratory diseases caused by rna viral infections Download PDF

Info

Publication number
WO2023192779A3
WO2023192779A3 PCT/US2023/064628 US2023064628W WO2023192779A3 WO 2023192779 A3 WO2023192779 A3 WO 2023192779A3 US 2023064628 W US2023064628 W US 2023064628W WO 2023192779 A3 WO2023192779 A3 WO 2023192779A3
Authority
WO
WIPO (PCT)
Prior art keywords
patients
treatment
diseases caused
viral infections
respiratory diseases
Prior art date
Application number
PCT/US2023/064628
Other languages
French (fr)
Other versions
WO2023192779A2 (en
Inventor
Alexandre Vasilievich IVACHTCHENKO
Alena Alexandrovna IVACHTCHENKO
Nikolay Filippovich Savchuk
Andrey Alexandrovich Ivashchenko
Ilya Andreevich IVASHCHENKO
Original Assignee
Asavi Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/709,608 external-priority patent/US20230310480A1/en
Priority claimed from US17/709,731 external-priority patent/US20230310544A1/en
Priority claimed from US17/709,609 external-priority patent/US20230310467A1/en
Priority claimed from US17/709,727 external-priority patent/US11648300B1/en
Application filed by Asavi Llc filed Critical Asavi Llc
Publication of WO2023192779A2 publication Critical patent/WO2023192779A2/en
Publication of WO2023192779A3 publication Critical patent/WO2023192779A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans

Abstract

The present application relates to the prevention and treatment of respiratory illnesses due to RNA virus infection in patients in need thereof. The application includes compositions of matter, pharmaceutical compositions, combinations, therapies, dosing regimens, methods, kits, etc. Some embodiments provide a therapeutically effective amount of aprotinin and an anti-RNA virus inhibitor selected from Remdesivir, Molnupiravir, Nirmatrelvir. Further embodiments are discussed in the specification.
PCT/US2023/064628 2022-03-31 2023-03-17 Combined prevention and treatment of patients with respiratory diseases caused by rna viral infections WO2023192779A2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US17/709,608 2022-03-31
US17/709,608 US20230310480A1 (en) 2022-03-31 2022-03-31 PHARMACEUTICAL COMBINATION THERAPY AND PREVENTION WITH APROTININ + MOLNUPIRAVIR OF SARS-CoV-2 AND/OR DISEASE ASSOCIATED WITH THIS INFECTION, INCLUDI COVID-19
US17/709,731 2022-03-31
US17/709,727 2022-03-31
US17/709,609 2022-03-31
US17/709,731 US20230310544A1 (en) 2022-03-31 2022-03-31 ANTI-RNA VIRAL PHARMACEUTICAL COMBINATION THERAPY WITH APROTININ + anti-RNA DRUG
US17/709,609 US20230310467A1 (en) 2022-03-31 2022-03-31 PHARMACEUTICAL COMBINATION THERAPY AND PREVENTION WITH APROTININ + REMDESIVIR OF SARS-CoV-2 AND/OR DISEASE ASSOCIATED WITH THIS INFECTION, INCLUDI COVID-19
US17/709,727 US11648300B1 (en) 2022-03-31 2022-03-31 Pharmaceutical combination therapy and prevention with aprotinin + nirmatrelvir of SARS-CoV-2 and/or disease associated with this infection, including COVID-19

Publications (2)

Publication Number Publication Date
WO2023192779A2 WO2023192779A2 (en) 2023-10-05
WO2023192779A3 true WO2023192779A3 (en) 2023-11-09

Family

ID=88203384

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/064628 WO2023192779A2 (en) 2022-03-31 2023-03-17 Combined prevention and treatment of patients with respiratory diseases caused by rna viral infections

Country Status (1)

Country Link
WO (1) WO2023192779A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210346416A1 (en) * 2020-05-05 2021-11-11 Ralph Lipp Pharmaceutical Compositions and Methods for their Use in Antiviral Therapy
US20210361688A1 (en) * 2020-05-22 2021-11-25 Carlos Alberto RIVEROS System, method and use of a certain medication for reducing viral replication in the airways mucosae
US20220000993A1 (en) * 2020-07-06 2022-01-06 Torvald Ranta Foretagsjuridik AB Drug for use against the novel coronavirus disease, covid-19
WO2022029334A1 (en) * 2020-08-07 2022-02-10 Gbiotech S.À.R.L. Combination therapies for treating coronavirus infection
WO2022039619A1 (en) * 2020-08-21 2022-02-24 Александр Васильевич ИВАЩЕНКО Antiviral agent for combined therapy of covid-19 (sars-cov-2)
US20220387541A1 (en) * 2021-06-07 2022-12-08 Global Preventive Medicine Biotech Company Limited Method and composition for preventing and treating covid-19 and long covid

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210346416A1 (en) * 2020-05-05 2021-11-11 Ralph Lipp Pharmaceutical Compositions and Methods for their Use in Antiviral Therapy
US20210361688A1 (en) * 2020-05-22 2021-11-25 Carlos Alberto RIVEROS System, method and use of a certain medication for reducing viral replication in the airways mucosae
US20220000993A1 (en) * 2020-07-06 2022-01-06 Torvald Ranta Foretagsjuridik AB Drug for use against the novel coronavirus disease, covid-19
WO2022029334A1 (en) * 2020-08-07 2022-02-10 Gbiotech S.À.R.L. Combination therapies for treating coronavirus infection
WO2022039619A1 (en) * 2020-08-21 2022-02-24 Александр Васильевич ИВАЩЕНКО Antiviral agent for combined therapy of covid-19 (sars-cov-2)
US20220387541A1 (en) * 2021-06-07 2022-12-08 Global Preventive Medicine Biotech Company Limited Method and composition for preventing and treating covid-19 and long covid

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IVASHCHENKO ANDREY A., ZAGRIBELNYY BOGDAN A., IVANENKOV YAN A., IVASHCHENKO ILYA A., KARAPETIAN RUBEN N., KRAVCHENKO DMITRY V., SA: "The Efficacy of Aprotinin Combinations with Selected Antiviral Drugs in Mouse Models of Influenza Pneumonia and Coronavirus Infection Caused by SARS-CoV-2", MOLECULES, MDPI AG, CH, vol. 27, no. 15, CH , pages 4975, XP093109219, ISSN: 1420-3049, DOI: 10.3390/molecules27154975 *

Also Published As

Publication number Publication date
WO2023192779A2 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
El Baba et al. Management of epigenomic networks entailed in coronavirus infections and COVID-19
CN112778310A8 (en) Application of nucleoside analogue or combination preparation containing nucleoside analogue in resisting virus
EP2338996A3 (en) Methods and compositions for reducing viral genome amounts in a target cell
JP2009504157A5 (en)
WO2021207409A3 (en) Small molecule inhibitors of sars-cov-2 viral replication and uses thereof
JP2017512193A5 (en)
RU2007141402A (en) METHODS FOR TREATING ASTHMA COMPLICATED BY INFECTIOUS DISEASES
CA2445744A1 (en) Antiviral nucleoside derivatives
EA201000085A1 (en) dsPHK INTRODUCED FOR THE TREATMENT OF VIRAL INFECTION
WO2006044968A3 (en) Combination therapy for treating viral infections
WO2008024843A3 (en) Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein
Cai et al. 14-Deoxy-11, 12-didehydroandrographolide attenuates excessive inflammatory responses and protects mice lethally challenged with highly pathogenic A (H5N1) influenza viruses
YU27203A (en) Pyrazole derivatives for the treatment of viral diseases
JP2022188083A5 (en)
WO2021242776A3 (en) Methods of treating inflammatory diseases by blocking galectin-3
MX2022006742A (en) Use and pharmaceutical composition of phenylisoxazolyl methylene-naphthalene-ether derivatives.
HUP0202734A2 (en) Use of pegylated interfron alfa-ccr5 antagonist combination for hiv therapy
Bereda Medications used for sars-cov-2 prophylaxis and treatment
JP2006507295A5 (en)
CA2504872A1 (en) Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections
CR20220508A (en) Pharmaceutical composition for preventing or treating epidemic rna viral infectious disease
WO2023192779A3 (en) Combined prevention and treatment of patients with respiratory diseases caused by rna viral infections
WO2005097618A3 (en) Low dose therapy for treating viral infections
Li et al. Role and Therapeutic Targeting Strategies of Neutrophil Extracellular Traps in Inflammation
WO2021205026A3 (en) Pharmaceutical composition for treatment of enveloped dna or rna virus induced infections and disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23781967

Country of ref document: EP

Kind code of ref document: A2